This therapy could be used to direct phagocytic anti-tumor immunity against tumor antigen expressing cells (e.g. human epidermal growth factor receptor (HER2), mesothelin) or use alongside CAR T cell therapies to improve T cell penetration into the sarcoma through ECM breakdown (254, 255). The gene discussed is MSLN; the disease is neoplasm.